Back to Journals » Risk Management and Healthcare Policy » Volume 16

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

Total article views   HTML views PDF downloads Totals
1,724 Dovepress* 1,639+ 56 1,695
PubMed Central* 85 32 117
Totals 1,724 88 1,812
*Since 15 November 2023

View citations on PubMed Central and Google Scholar